Phase 2 RCT of MK2 inhibitor did not show clinical efficacy at week 12 in active AS pts compared to PBO. There are still unmet needs for additional therapeutics in pts with AS that not respond to current therapies. Abst#1760 #ACR24 @RheumNow https://t.co/cXv8HYr0Xr

• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1
• https://x.com/AdelaCastro222/status/1858263006217400826/photo/1

SURPASS trial of bio naïve axSpA at risk of radiographic progression: 1. Presence of syndesmophytes 2. Higher CRP levels 3. Higher ASDAS 4. Higher spinal MRI BME scores Were predictors of spinal progression independent of ttnt Abst#1759 #ACR24 @RheumNow https://t.co/QC9FMPufPY

• https://x.com/AdelaCastro222/status/1858257553966141559/photo/1
• https://x.com/AdelaCastro222/status/1858257553966141559/photo/1

Dr. BDinneen et al reported predictors that can help screen axSpA pts w/o traditional CV RFs for carotid doppler utz: - shorter dse duration - no family hx of IHD - HLAB27+ - ⬆️ dBP, WHratio, ferritin, TC, LDL and TC:HDL ratio Small size, more data reqd @RheumNow #ACR24 abs1440 https://t.co/3pZxFmutJz

• https://x.com/RHEUMarampa/status/1858257932665659735/photo/1
• https://x.com/RHEUMarampa/status/1858257932665659735/photo/1

The odds of axSpA patients developing fractures was lower among those on TNFi vs DMaRDs or NSAIDs accdg to this study by NGeorge et al. axSpA pts are at high risk of fractures & drugs that mitigate these risks are important. More robust data are needed @RheumNow #ACR24 abs1439 https://t.co/ZSV3og5N5x

• https://x.com/RHEUMarampa/status/1858252752427626764/photo/1

Single cell TCR sequence study explores the limitations of TRBV9-depleting therapies in axial spondyloarthritis. Key findings: - Identified a clonally expanded TRBV5-5+ TCR in HLA-B27+ acute anterior uveitis. - Alternative TRBVs may retain pathogenicity and evade anti-TRBV9… https://t.co/Aj8oslsTNX

• https://x.com/i/web/status/1858246230763253795

📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52. -PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52. Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9

• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1
• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1

In a cohort of >17,000 European pts w/ axSpA: -bDMARD naïve pts starting TNFi or IL-17Ai were more likely to achieve LDA than TNF-experienced. -Higher time to achieve LDA and shorter durability in pts with prior TNFi use. Abst#1756 #ACR24 @RheumNow

Study revealing the Uterine-Joint Axis in female axial spondyloarthritis, highlighting dysbiosis and subclinical uterine inflammation as key factors in disease pathogenesis. Key findings: - Distinct microbiota profiles in AxSpA patients vs. healthy controls. - Significant genital… https://t.co/Cl12ELdjI2

• https://x.com/i/web/status/1858238682848784496

BE MOBILE 1 & 2: Bimekizumab resulted in improvement of SIJ MRI inflammation & structural lesions particularly after 16 wks of treatment and continued on until wk. 52. Supports addtl evidence of BKZ's winning streak in #axSpA @RheumNow #ACR24 abs1757 https://t.co/EUntQIuQC8

• https://x.com/RHEUMarampa/status/1858231890827706410/photo/1